Compare Enbridge Inc (ENB) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Incyte Corporation — how do they compare? Enbridge Inc trades at $56.23 (market cap $121.39B), while Incyte Corporation trades at $115 (market cap $22.99B). The key difference: Enbridge Inc is far larger — about 5.3× Incyte Corporation's market cap, and Enbridge Inc pays a 5.01% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| ENB | INCY | |
|---|---|---|
Market Cap | $121.39B | $22.99B |
Sector | Energy | Health |
52-Week High | $58.04 | $118.52 |
52-Week Low | $44.59 | $67.38 |
Enterprise Value | $202.19B | $19.01B |
Dividend Yield | 5.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENB trades at $56.20, up 0.55% with a bullish technical outlook. Recent earnings show mixed results with Q1 2026 beating estimates but Q3 2025 missing. The company maintains strong cash flow from operations of $12.27B in 2025 and a 5.1% dividend yield. Revenue grew to $65.19B in 2025, with net income margin at 10%. Analyst consensus is evenly split between Buy and Hold ratings.
Outlook remains positive due to $28B in growth projects and stable dividends, but risks include high debt levels (debt-to-asset ratio 48.81% in 2025) and sensitivity to energy market volatility. The stock offers income appeal but faces execution risks on capital expenditures.
INCY trades at $115.83, up 0.83% today, with a bullish technical signal from moving averages and strong fundamental performance including 2025 revenue of $5.14B and net income of $1.29B. Recent developments include positive Phase 1/2 data for VGA039 presented at ISTH 2026 and the acquisition of Vega Therapeutics, expanding its hematology portfolio. The stock shows robust profitability with a 26.71% net income margin and 30.82% ROE, while analyst consensus is a Buy with a $112.78 price target.
Outlook remains positive driven by pipeline advancements and earnings growth, though risks include clinical trial outcomes and regulatory hurdles. The current price above the consensus target suggests limited near-term upside, but continued execution could support further gains. Investors should weigh strong cash flow generation against competitive pressures in the biopharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
